Medicenna Therapeutics Stock Forward View
| MDNA Stock | CAD 0.77 -0.03 -3.75% |
Investor sentiment around Medicenna Therapeutics can cause the stock to overshoot or undershoot its fair value for extended periods. This module tracks sentiment signals to identify when that divergence is likely to correct.
As reflected in current metrics, Medicenna Therapeutics posts the 14-period RSI reading of 39, reflecting mild downside bias. Momentum in this band leans bearish but lacks the intensity that typically precedes a sharp move lower.Momentum
Sell Extended
Oversold | Overbought |
The hype view outlines Medicenna Therapeutics' attention response alongside peer coverage.
The Naive Prediction forecasted value of Medicenna Therapeutics Corp on the next trading day is expected to be 0.71 with a mean absolute deviation of 0.02 and the sum of the absolute errors of 1.45.Medicenna Therapeutics after-hype prediction price | C$ 0.77 |
The sentiment summary complements forecasting and technical views with analyst estimates and earnings data.
Medicenna |
Medicenna Therapeutics Additional Predictive Modules
Most predictive techniques to examine Medicenna price help traders to determine how to time the market. We provide a combination of tools to recognize potential entry and exit points for Medicenna using various technical indicators. When you analyze Medicenna charts, please remember that the event formation may indicate an entry point for a short seller, and look at other indicators across different periods to confirm that a breakdown or reversion is likely to occur.| Cycle Indicators | ||
| Math Operators | ||
| Math Transform | ||
| Momentum Indicators | ||
| Overlap Studies | ||
| Pattern Recognition | ||
| Price Transform | ||
| Statistic Functions | ||
| Volatility Indicators | ||
| Volume Indicators |
Naive Prediction Price Forecast For the 14th of March 2026
Given 90 days horizon, the Naive Prediction forecasted value of Medicenna Therapeutics Corp on the next trading day is expected to be 0.71 with a mean absolute deviation of 0.02 , mean absolute percentage error of 0.001 , and the sum of the absolute errors of 1.45 .Please note that although there have been many attempts to predict Medicenna Stock prices using its time series forecasting, we generally do not suggest using it to place bets in the real market. The most commonly used models for forecasting predictions are the autoregressive models, which specify that Medicenna Therapeutics' next future price depends linearly on its previous prices and some stochastic term (i.e., imperfectly predictable multiplier).
Stock Forecast Pattern
| Backtest Medicenna Therapeutics | Medicenna Therapeutics Price Prediction | Research Analysis |
Forecasted Value
This next-day forecast for Medicenna Therapeutics Corp uses model performance to estimate practical downside and upside boundaries rather than a single point target alone. Investors should still remember that no empirical framework consistently proves that one family of forecasting models will outperform all other approaches in live markets.
Model Predictive Factors
The below table displays some essential indicators generated by the model showing the Naive Prediction forecasting method's relative quality and the estimations of the prediction error of Medicenna Therapeutics stock data series using in forecasting. Note that when a statistical model is used to represent Medicenna Therapeutics stock, the representation will rarely be exact; so some information will be lost using the model to explain the process. AIC estimates the relative amount of information lost by a given model: the less information a model loses, the higher its quality.| AIC | Akaike Information Criteria | 111.1616 |
| Bias | Arithmetic mean of the errors | None |
| MAD | Mean absolute deviation | 0.0237 |
| MAPE | Mean absolute percentage error | 0.0267 |
| SAE | Sum of the absolute errors | 1.4474 |
Investors who believe in mean reversion view Medicenna Therapeutics' price extremes not as permanent states but as temporary dislocations that create opportunities for disciplined, contrarian capital allocation.
After-Hype Price Density Analysis
The shape of Medicenna Therapeutics' price distribution after major news events tends to be skewed, with larger potential moves to the downside than to the upside for established companies like Medicenna Therapeutics. This asymmetry is a key input for options pricing and risk management.
Next price density |
| Expected price to next headline |
Estimiated After-Hype Price Volatility
By studying Medicenna Therapeutics' historical news reactions, we generate empirical estimates of the price boundaries that follow significant headlines. Medicenna Therapeutics' after-hype downside and upside margins for the prediction period are 0.04 and 4.16, respectively. These estimates are most reliable when Medicenna Therapeutics's news reaction patterns have been consistent over multiple events.
Current Value
The after-hype framework applied to Medicenna Therapeutics Corp assumes a 3 months review window and focuses on post-sentiment normalization rather than raw momentum. This view is most useful when investors want to compare sentiment-driven price extension with a more measured post-news scenario.
Price Outlook Analysis
Have you ever been surprised when a price of a Company such as Medicenna Therapeutics is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading Medicenna Therapeutics backward and forwards among themselves. Have you ever observed a lot of a particular company's price movement is driven by press releases or news about the company that has nothing to do with actual earnings? Usually, hype to individual companies acts as price momentum. If not enough favorable publicity is forthcoming, the Stock price eventually runs out of speed. So, the rule of thumb here is that as long as this news hype has nothing to do with immediate earnings, you should pay more attention to it. If you see this tendency with Medicenna Therapeutics, there might be something going there, and it might present an excellent short sale opportunity.
| Expected Return | Period Volatility | Hype Elasticity | Related Elasticity | News Density | Related Density | Expected Hype |
0.47 | 3.39 | 0.00 | 0.00 | 0 Events | 0 Events | Uncertain |
| Latest traded price | Expected after-news price | Potential return on next major news | Average after-hype volatility | |
0.77 | 0.77 | 0.00 |
|
Hype Timeline
Medicenna Therapeutics is now traded for 0.77on Toronto Exchange of Canada. The company stock is not elastic to its hype. The average elasticity to hype of competition is 0.0. Medicenna is estimated not to react to the next headline, with the price staying at about the same level, and average media hype impact volatility is insignificant. The immediate return on the next news is estimated to be very small, whereas the daily expected return is now at -0.47%. %. The volatility of related hype on Medicenna Therapeutics is about 0.0%, with the expected price after the next announcement by competition of 0.77. About 21.0% of the company outstanding shares are owned by corporate insiders. The company recorded a loss per share of 0.15. Medicenna Therapeutics last dividend was issued on the 3rd of March 2017. The company completed a 1:14 stock split on 3rd of March 2017. Assuming the 90-day trading horizon the next estimated press release will be uncertain. Cross-verify projections for Medicenna Therapeutics using Historical Fundamental Analysis of Medicenna Therapeutics. The analysis adds historical context for the projection set.Related Hype Analysis
News about regulatory changes, technological disruptions, or macroeconomic shifts can affect Medicenna Therapeutics' entire competitive landscape simultaneously. Monitoring peer reactions to such events helps investors anticipate Medicenna Therapeutics's likely response.
| HypeElasticity | NewsDensity | SemiDeviation | InformationRatio | PotentialUpside | ValueAt Risk | MaximumDrawdown | |||
| MSCL | Satellos Bioscience | 0.00 | 0 per month | 5.64 | 0.15 | 8.64 | -7.37 | 32.73 | |
| MIR | MedMira | 0.00 | 0 per month | 0.00 | -0.01 | 14.29 | -12.50 | 30.95 | |
| ARCH | Arch Biopartners | 0.00 | 0 per month | 0.00 | -0.14 | 4.49 | -8.20 | 34.73 | |
| ZEN | ZEN Graphene Solutions | 0.00 | 0 per month | 4.31 | 0.01 | 8.86 | -8.00 | 31.63 | |
| SVA | Sernova Corp | 0.00 | 0 per month | 2.68 | 0.1 | 7.69 | -6.67 | 27.31 | |
| COV | Covalon Technologies | 0.00 | 0 per month | 2.06 | 0.02 | 5.03 | -3.16 | 16.20 | |
| MDP | Medexus Pharmaceuticals | 0.00 | 0 per month | 1.77 | 0.12 | 4.84 | -3.51 | 13.99 |
Other Forecasting Options for Medicenna Therapeutics
Investors at all stages of experience who consider Medicenna must develop an understanding of Medicenna Therapeutics' price dynamics. The noise embedded in Medicenna Stock price charts can create misleading signals and skew investment decisions.Medicenna Therapeutics Related Equities
The following equities are related to Medicenna Therapeutics within the Health Care space and can be used for peer comparison, relative valuation, or portfolio diversification. Comparing Medicenna Therapeutics against peers on metrics such as P/E, margins, and return on equity helps contextualize its positioning and identify relative strengths or weaknesses.
| Risk & Return | Correlation |
Medicenna Therapeutics Market Strength Events
Market strength indicators applied to Medicenna Therapeutics stock give investors a structured view of the security's momentum relative to the overall market. Using these indicators, traders can refine their timing when entering or exiting positions in Medicenna Therapeutics Corp.
Medicenna Therapeutics Risk Indicators
Evaluating Medicenna Therapeutics' risk indicators is an important step in accurately forecasting its price and assessing the suitability of an investment. Understanding the risk profile of Medicenna Therapeutics' allows investors to make more informed decisions about position sizing and risk.
| Mean Deviation | 2.59 | |||
| Standard Deviation | 3.39 | |||
| Variance | 11.51 |
Please note, the risk measures we provide can be used independently or collectively to perform a risk assessment. When comparing two potential investments, we recommend comparing similar equities with homogenous growth potential and valuation from related markets to determine which investment holds the most risk.
Story Coverage note for Medicenna Therapeutics
Coverage intensity for Medicenna Therapeutics Corp matters because narrative visibility can influence sentiment, participation, and volatility around the name. The stronger process compares story flow with performance, theme classification, and the level of short-term market interest.
Other Macroaxis Stories
Story coverage on Macroaxis is built for readers who approach markets from different levels of experience but share the same need for disciplined investment context. Used well, these stories become part of a broader workflow built around idea generation, validation, and risk-adjusted portfolio design.
Story Categories
Currently Trending Categories
Medicenna Therapeutics Short Properties
Short sentiment tied to Medicenna Therapeutics Corp matters because heavier bearish pressure can change how quickly future price expectations become unstable. Used correctly, these measures can help investors decide when hedging or timing discipline may matter more than conviction alone.
| Common Stock Shares Outstanding | 76.7 M | |
| Cash And Short Term Investments | 24.8 M |
More Resources for Medicenna Stock Analysis
Other Information on Investing in Medicenna Stock
Financial ratios for Medicenna Therapeutics provide valuation context across profits, cash flow, and enterprise value. They help compare Medicenna across valuation measures in a consistent way.